


Data Sheet (Cat.No.T17174)

Troriluzole

Chemical Properties

| | |
|-------------------|--|
| CAS No.: | 1926203-09-9 |
| Formula: | C ₁₅ H ₁₆ F ₃ N ₅ O ₄ S |
| Molecular Weight: | 419.38 |
| Appearance: | N/A |
| Storage: | 0-4°C for short term (days to weeks), or -20°C for long term (months). |



Biological Description

| | |
|----------------------------|--|
| Description | Troriluzole is an orally active glutamate modulator. Troiriluzole reduces the synaptic glutamate level and increases synaptic glutamate absorption. |
| Targets(IC ₅₀) | glutamate: None |
| In vitro | Troriluzole is absorbed systemically and cleaves into riluzole by aminopeptidases. Troiriluzole has the potential for Alzheimer's disease and generalized anxiety disorder [1][2]. |

Solubility Information

| | |
|------------|---|
| Solubility | < 1 mg/ml refers to the product slightly soluble or insoluble |
|------------|---|

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|----------|-----------|-----------|
| 1 mM | 2.384 mL | 11.922 mL | 23.845 mL |
| 5 mM | 0.477 mL | 2.384 mL | 4.769 mL |
| 10 mM | 0.238 mL | 1.192 mL | 2.384 mL |
| 50 mM | 0.048 mL | 0.238 mL | 0.477 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

- Schanzer B, et al. Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opin Investig Drugs. 2019 Nov;28(11):1003-1012.
- Huang LK, et al. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020 Jan 6;27(1):18.

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street,Wellesley Hills,MA 02481